Home » Stocks » ADMP

Adamis Pharmaceuticals Corporation (ADMP)

Stock Price: $0.745 USD 0.008 (1.10%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $0.755 +0.010 (1.30%) May 7, 7:56 PM
Market Cap 114.54M
Revenue (ttm) 16.53M
Net Income (ttm) -49.39M
Shares Out 77.57M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.745
Previous Close $0.737
Change ($) 0.008
Change (%) 1.10%
Day's Open 0.743
Day's Range 0.740 - 0.833
Day's Volume 11,659,991
52-Week Range 0.376 - 2.340

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021

3 weeks ago - GlobeNewsWire

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, al...

3 weeks ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has provided an update on its marketing application's status seeking approval for Zimhi's high-dose naloxone injection product to treat opioid overdose....

3 weeks ago - Benzinga

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company's New Drug Application (NDA) relating to its ZIMHI™ ...

3 weeks ago - GlobeNewsWire

Adamis Pharmaceuticals shares were up in January on the news of its Covid-19 treatment trial, but ADMP stock has been sliding since. The post Wait for Q4 Earnings Before Making Any Move on Adamis Pharma...

1 month ago - InvestorPlace

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has reported positive data from lab studies conducted in animal models. The study showed that Tempol-treated hamsters challenged with COVID-19 infection achiev...

1 month ago - Benzinga

SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University o...

1 month ago - GlobeNewsWire

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety re...

2 months ago - GlobeNewsWire

U.S. Patent and Trademark Office has allowed a patent to one of the patent applications by Adamis Pharmaceuticals Corp (NASDAQ: ADMP) related to its ZIMHI high-dose naloxone injection product candidate,...

2 months ago - Benzinga

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, ...

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therap...

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therap...

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of ...

3 months ago - GlobeNewsWire

Adamis Pharmaceuticals finished 2020 with some Malheur with the company receiving its second CRL for ZIMHI. However, the company is a making a strong comeback thus far in 2021. Adamis plans to appeal th...

3 months ago - Seeking Alpha

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focu...

Other stocks mentioned: FLDM, SEEL, BCRX
3 months ago - Benzinga

Adamis Pharma (ADMP) stock is taking off on Friday after a week of positive news for the company, including a deal with Walgreens. The post ADMP Stock: 4 Things to Know About Adamis Pharma Today as Shar...

3 months ago - InvestorPlace

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members of the Walg...

3 months ago - GlobeNewsWire

Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.

3 months ago - Zacks Investment Research

Adamis Pharma (ADMP) stock is taking off on Wednesday following news of its possible treatment for the novel coronavirus. The post ADMP Stock Alert: The Covid-19 Treatment News That Has Adamis Pharma Sh...

3 months ago - InvestorPlace

SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigation...

3 months ago - GlobeNewsWire

Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it recei...

5 months ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Adamis (ADMP) delivered earnings and revenue surprises of -150.00% and -47.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business up...

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, 2020 at 2:...

6 months ago - GlobeNewsWire

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various the...

7 months ago - GlobeNewsWire

SAN DIEGO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various the...

7 months ago - GlobeNewsWire

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was initially he...

8 months ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Adamis (ADMP) delivered earnings and revenue surprises of -85.71% and -21.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SAN DIEGO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provided a busin...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with t...

8 months ago - GlobeNewsWire

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYM...

10 months ago - GlobeNewsWire

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of coronavirus ...

10 months ago - Benzinga

SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license  to commercialize Tempol, a novel patented investigational drug fo...

10 months ago - GlobeNewsWire

Adamis recently reported their Q1 earnings with a miss on EPS and revenue. The COVID-19 pandemic has had a significant impact on the company's US Compounding sales.

11 months ago - Seeking Alpha

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a business update.

11 months ago - GlobeNewsWire

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) Injection 0...

11 months ago - GlobeNewsWire

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

SAN DIEGO, April 23, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Intramuscular...

1 year ago - GlobeNewsWire

SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has increase...

1 year ago - GlobeNewsWire

Adamis Pharmaceuticals: Trying To Find A Course Of Action

1 year ago - Seeking Alpha

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Paycheck Prote...

1 year ago - GlobeNewsWire

About ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candida... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Dennis Carlo
Employees
116
Stock Exchange
NASDAQ
Ticker Symbol
ADMP
Full Company Profile

Financial Performance

In 2020, ADMP's revenue was $16.53 million, a decrease of -25.26% compared to the previous year's $22.11 million. Losses were -$49.39 million, 79.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ADMP stock is "Buy." The 12-month stock price forecast is 1.00, which is an increase of 34.17% from the latest price.

Price Target
$1.00
(34.17% upside)
Analyst Consensus: Buy